Presented herein are personalized compositions comprising iPSCs and/or iPSC-derived cells (cells) and methods of producing personalized compositions suitable for various therapies, including chondrogenesis therapies, to be administered to an individual or a group of individuals. The cells and/or cell lines, and any compositions derived therefrom, are identified as compatible with a specific individual or specific group of individuals using an identification of a cell type indicative of compatibility such as an HLA match. The compatible cells are then used to derive “personalized” compositions, wherein the “personalized” compositions comprise one or more cell-secreted molecules suitable for therapy. It is found herein that a composition comprising one or more iPSC-derived MSCs, iPSC-derived chondrocytes, and iPSC-derived chondrons may provide improved treatment efficacy than would be offered by bone marrow-MSCs (BM-MSCs) or compositions comprising BM-MSCs.本文中呈現包含iPSC及/或源自iPSC之細胞(細胞等)之個人化組合物及製備待向個體或個體群投與之適用於各種療法，包括軟骨生成療法之個人化組合物的方法。該等細胞及/或細胞株及源自其之任何組合物係使用指示諸如HLA匹配之相容性之細胞類型的鑑別被鑑別為與特定個體或特定個體群相容。該等相容細胞隨後用於衍生「個人化」組合物，其中該等「個人化」組合物包含一或多種適用於療法之細胞分泌分子。本文中發現，包含一或多種源自iPSC之MSC、源自iPSC之軟骨細胞及源自iPSC之軟骨單位的組合物可提供相比骨髓-MSC (BM-MSC)或包含BM-MSC之組合物所提供之治療功效有所改善之治療功效。
